Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Cancer Res. 2010 Apr 13;70(9):3606–3617. doi: 10.1158/0008-5472.CAN-09-4598

Figure 3.

Figure 3

A, the expression of COX-2, E-cadherin, PTEN, pAkt, tropomyosin, and β-actin in BxPC-3, MIAPaCa-E, and MIAPaCa-M cell lines treated with 1 to 4 μmol/L CDF/curcumin, 10 nmol/L gemcitabine, or the combination for 72 h. B, comparative expression analysis of miR-21 in BxPC-3, MIAPaCa-E, and MIAPaCa-M cells by real-time miRNA RT-PCR. Cells were treated with 1 to 4 μmol/L CDF/curcumin, 10 nmol/L gemcitabine, or their combinations for 72 h. The expression of PTEN, pAkt, and NF-κB in MIAPaCa-E cells after transfection with miR-21 antisense oligo (C) and transfection with PTEN cDNA (D), followed by gemcitabine treatment for 48 h.